,PMCID,sentence
0,PMC3923659,"""1"" colspan=""1"">c-Jun, JUN</td>
                  <td align=""left"" rowspan=""1"" colspan=""1"">1jnmA, 1fosF</td>
                  <td align=""left"" rowspan=""1"" colspan=""1"">4</td>
                  <td align="
1,PMC3923659,"eft"" rowspan=""1"" colspan=""1"">1ukh</td>
                  <td align=""left"" rowspan=""1"" colspan=""1"">1fosF</td>
                  <td align=""left"" rowspan=""1"" colspan=""1"">3</td>
                  <td align="
2,PMC3923659,"ft"" rowspan=""1"" colspan=""1"">1fosE</td>
                  <td align=""left"" rowspan=""1"" colspan=""1"">1fosF</td>
                  <td align=""left"" rowspan=""1"" colspan=""1"">3</td>
                  <td align="
3,PMC3923659,"            </tr>
                <tr>
                  <td align=""left"" rowspan=""1"" colspan=""1"">1fosF</td>
                  <td align=""left"" rowspan=""1"" colspan=""1"">2r9s</td>
                  <td ali"
0,PMC3952815,">[7]</xref>, <xref rid=""pcbi.1003495-Marten1"" ref-type=""bibr"">[13]</xref>, <xref rid=""pcbi.1003495-Hosford1"" ref-type=""bibr"">[42]</xref>, <xref rid=""pcbi.1003495-Destexhe4"" ref-type=""bibr"">[43]</xref>. T"
1,PMC3952815,"ynamical Systems. Philadelphia PA: SIAM.</mixed-citation>
      </ref>
      <ref id=""pcbi.1003495-Hosford1"">
        <label>42</label>
        <mixed-citation publication-type=""journal"">
<name><surname>"
2,PMC3952815,"rd1"">
        <label>42</label>
        <mixed-citation publication-type=""journal"">
<name><surname>Hosford</surname><given-names>DA</given-names></name>, <name><surname>Clark</surname><given-names>S</giv"
0,PMC3998880,"pe=""journal"">
<name><surname>Dehouck</surname><given-names>Y</given-names></name>, <name><surname>Grosfils</surname><given-names>A</given-names></name>, <name><surname>Folch</surname><given-names>B</give"
0,PMC4014389,"ames></name>, <name><surname>Lasarge</surname><given-names>CL</given-names></name>, <name><surname>Hosford</surname><given-names>BE</given-names></name>, <name><surname>Rosen</surname><given-names>JM</gi"
0,PMC4102405,"pe=""journal"">
<name><surname>Dehouck</surname><given-names>Y</given-names></name>, <name><surname>Grosfils</surname><given-names>A</given-names></name>, <name><surname>Folch</surname><given-names>B</give"
0,PMC4102429,"-names></name>, <name><surname>Vincze</surname><given-names>T</given-names></name>, <name><surname>Posfai</surname><given-names>J</given-names></name>, <name><surname>Macelis</surname><given-names>D</giv"
0,PMC4125052,"tal trials in the vicinity of susceptible commercial growing operations <xref rid=""pcbi.1003753-SantosFilho1"" ref-type=""bibr"">[18]</xref>, <xref rid=""pcbi.1003753-Martins1"" ref-type=""bibr"">[19]</xref>.</"
1,PMC4125052," for pathogens which cannot be effectively controlled by chemical means <xref rid=""pcbi.1003753-SantosFilho1"" ref-type=""bibr"">[18]</xref>, <xref rid=""pcbi.1003753-Martins1"" ref-type=""bibr"">[19]</xref>. V"
2,PMC4125052,"49</fpage>&#x2013;<lpage>156</lpage>.</mixed-citation>
      </ref>
      <ref id=""pcbi.1003753-SantosFilho1"">
        <label>18</label>
        <mixed-citation publication-type=""journal"">
<name><surname"
0,PMC4133158,"5</fpage>&#x2013;<lpage>11059</lpage>.</mixed-citation>
      </ref>
      <ref id=""pcbi.1003759-RamosFernndez1"">
        <label>18</label>
        <mixed-citation publication-type=""journal"">
<name><surn"
0,PMC4383532,"acelis, Shelly Glashow, David Lipman, Rahmah Mohamed, Chris Noren, Karen Otto, Mila Pollock, Janos Posfai, Ira Schildkraut, Barton Slatko, and, last but not least, my wife, Jean, whose comments cannot be"
0,PMC4537296,"-names></name>, <name><surname>Vincze</surname><given-names>T</given-names></name>, <name><surname>Posfai</surname><given-names>J</given-names></name>, <name><surname>Macelis</surname><given-names>D</giv"
0,PMC4849740,"es are available from the Open Science Framework (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/jf42a"">https://osf.io/jf42a</ext-link>).</meta-value>
        </custom-meta>
      </custom-meta"
1,PMC4849740,"the Open Science Framework (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/jf42a"">https://osf.io/jf42a</ext-link>).</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-"
2,PMC4849740,"es are available from the Open Science Framework (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/jf42a"">https://osf.io/jf42a</ext-link>).</p>
    </notes>
  </front>
  <body>
    <sec sec-type="
3,PMC4849740,"the Open Science Framework (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/jf42a"">https://osf.io/jf42a</ext-link>).</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" id=""sec001"">
 "
4,PMC4849740," all of our simulations are available publicly at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/jf42a"">https://osf.io/jf42a</ext-link>, except in the cases when the stimulus set is already ava"
5,PMC4849740,"s are available publicly at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/jf42a"">https://osf.io/jf42a</ext-link>, except in the cases when the stimulus set is already available online (links t"
0,PMC4880440,"e>The data from this paper can be found online at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/u57df"">https://osf.io/u57df</ext-link>.</meta-value>
        </custom-meta>
      </custom-meta-"
1,PMC4880440,"aper can be found online at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/u57df"">https://osf.io/u57df</ext-link>.</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-m"
2,PMC4880440,"p>The data from this paper can be found online at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/u57df"">https://osf.io/u57df</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type="""
3,PMC4880440,"aper can be found online at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/u57df"">https://osf.io/u57df</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" id=""sec001"">
  "
0,PMC4894630,"ailable on the Open Science Framework database at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/dm9g8/"">https://osf.io/dm9g8/</ext-link>.</meta-value>
        </custom-meta>
      </custom-met"
1,PMC4894630,"ence Framework database at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/dm9g8/"">https://osf.io/dm9g8/</ext-link>.</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-"
2,PMC4894630,"ailable on the Open Science Framework database at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/dm9g8/"">https://osf.io/dm9g8/</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type"
3,PMC4894630,"ence Framework database at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/dm9g8/"">https://osf.io/dm9g8/</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" id=""sec001"">
 "
0,PMC4944922,"le from the Open Science Framework database (URL: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/my2zq"">https://osf.io/my2zq</ext-link>).</meta-value>
        </custom-meta>
      </custom-meta"
1,PMC4944922,"ce Framework database (URL: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/my2zq"">https://osf.io/my2zq</ext-link>).</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-"
2,PMC4944922,"le from the Open Science Framework database (URL: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/my2zq"">https://osf.io/my2zq</ext-link>).</p>
    </notes>
  </front>
  <body>
    <sec sec-type="
3,PMC4944922,"ce Framework database (URL: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/my2zq"">https://osf.io/my2zq</ext-link>).</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" id=""sec001"">
 "
0,PMC4954710,"n-names></name>, <name><surname>Engel</surname><given-names>S</given-names></name>, <name><surname>Kosfeld</surname><given-names>M</given-names></name>. <article-title>Conditional cooperation and costly "
0,PMC4982667,"en-names></name>, <name><surname>Gaal</surname><given-names>T</given-names></name>, <name><surname>Posfai</surname><given-names>G</given-names></name>. <article-title>Engineered ribosomal RNA operon copy"
0,PMC4999195,"ng clinical and experimental data, to explore a spectrum of treatment regimens combining a HAP, evofosfamide, with erlotinib. We design combination toxicity constraint models and optimize treatment strat"
1,PMC4999195,"i) combining these therapies delays resistance longer than any monotherapy schedule with either evofosfamide or erlotinib alone, (ii) sequentially alternating single doses of each drug leads to minimal t"
2,PMC4999195,"obability of developing resistance, and (iii) strategies minimizing the length of time after an evofosfamide dose and before erlotinib confer further benefits in reduction of tumor burden. These results "
3,PMC4999195,"i) combining these therapies delays resistance longer than any monotherapy schedule with either evofosfamide or erlotinib alone, and (ii) the best strategy for combination involves single doses of each d"
4,PMC4999195,"013;<xref rid=""pcbi.1005077.ref018"" ref-type=""bibr"">18</xref>]. For example, one such compound, evofosfamide, consists of a radical anion linked to a potent DNA-alkylating agent which penetrates effectiv"
5,PMC4999195,">, <xref rid=""pcbi.1005077.ref019"" ref-type=""bibr"">19</xref>]. This type of novel action allows evofosfamide to penetrate and target cancer cells within hypoxic region of a tumor, unlike standard therapi"
6,PMC4999195,"ficient tissue penetration were the primary contributing factors to this result. More recently, evofosfamide, which has a superior tissue-penetration ability, underwent Phase III testing in combination w"
7,PMC4999195,"ll population within a heterogeneous tumor microenvironment during treatment with erlotinib and evofosfamide. Using this model, we show that a combination treatment strategy results in treatment outcomes"
8,PMC4999195," an evolutionary mathematical modeling approach to evaluate the impact of combination erlotinib-evofosfamide therapy on a NSCLC tumor cell population, in which each tumor cell response is dependent upon "
9,PMC4999195,"d erlotinib concentration, (ii) published experimental results on cell viability in response to evofosfamide therapy, (iii) tumor oxygenation measurements, and (iv) pharmacokinetic data mapping evofosfam"
10,PMC4999195,"ofosfamide therapy, (iii) tumor oxygenation measurements, and (iv) pharmacokinetic data mapping evofosfamide and erlotinib dose to plasma concentration. We also utilize clinical trial data for both thera"
11,PMC4999195,"ariation, we first define distinct functions describing the individual effects of erlotinib and evofosfamide on these birth and death rates. The growth kinetics of the cancer cell population during treat"
12,PMC4999195,"ions, functions pertaining to erlotinib are denoted with 1&#x2019;s and functions pertaining to evofosfamide are denoted using 2&#x2019;s. We note that the birth and death rates used in this parameteriza"
13,PMC4999195,"tion>
              <title>Net growth rate and plasma concentration functions for erlotinib and evofosfamide.</title>
              <p>Examples of net growth rates of sensitive and resistant cells are sh"
14,PMC4999195,"s of sensitive and resistant cells are shown as functions of erlotinib concentration in (A) and evofosfamide concentration in (C). These rates are shown in blue for a low oxygen concentration (0.33%), co"
15,PMC4999195," rates. Examples of plasma concentration functions over time are shown for erlotinib in (B) and evofosfamide in (D). Given a standard dosing schedule of 150 mg erlotinib administered daily, the red curve"
16,PMC4999195,"artment furthest from the nearest blood vessel. (D) shows an example of a periodic function for evofosfamide plasma concentration over time, given a dosing schedule of 575 mg/m<sup>2</sup> administered w"
17,PMC4999195,"</label></disp-formula></p>
        </sec>
        <sec id=""sec006"">
          <title>Effect of evofosfamide and oxygen on growth kinetics</title>
          <p>Next we consider the effect of evofosfamide"
18,PMC4999195," evofosfamide and oxygen on growth kinetics</title>
          <p>Next we consider the effect of evofosfamide on the erlotinib-sensitive and erlotinib-resistant cell populations in each microenvironmental"
19,PMC4999195,"ironmental compartment. Note that the mechanisms of action differ greatly between erlotinib and evofosfamide. In particular, the mutation conferring resistance to erlotinib occurs in the EGFR kinase doma"
20,PMC4999195, resistance to erlotinib occurs in the EGFR kinase domain which is independent of the action of evofosfamide; thus the presence of this mutation is not thought to impact evofosfamide response. So we assu
21,PMC4999195,dent of the action of evofosfamide; thus the presence of this mutation is not thought to impact evofosfamide response. So we assume the same response of erlotinib-sensitive and erlotinib-resistant cells 
22,PMC4999195,esponse. So we assume the same response of erlotinib-sensitive and erlotinib-resistant cells to evofosfamide. The net growth rate dependence on evofosfamide concentration in each microenvironmental compa
23,PMC4999195,inib-sensitive and erlotinib-resistant cells to evofosfamide. The net growth rate dependence on evofosfamide concentration in each microenvironmental compartment is calculated from cell viability experim
24,PMC4999195,"2C</xref> for a low oxygen concentration (0.33%) and a high oxygen concentration (10.5%). Since evofosfamide releases a cytotoxic agent in hypoxic regions, we assume that its primary effect is to increas"
25,PMC4999195,"irth and death rates of sensitive cells in compartment <italic>i</italic> during treatment with evofosfamide by <inline-formula id=""pcbi.1005077.e024""><alternatives><graphic xlink:href=""pcbi.1005077.e024"
26,PMC4999195,"ates of resistant cells in compartment <italic>i</italic>.</p>
          <p><italic>Analysis of evofosfamide pharmacokinetic data.</italic> Next we consider how the concentration of evofosfamide changes "
27,PMC4999195,alysis of evofosfamide pharmacokinetic data.</italic> Next we consider how the concentration of evofosfamide changes during treatment. The plasma concentration after a dose of <italic>D</italic><sub>2</s
28,PMC4999195,"nt. The plasma concentration after a dose of <italic>D</italic><sub>2</sub> mg/m<sup>2</sup> of evofosfamide as a function of time is given by:
<disp-formula id=""pcbi.1005077.e028""><alternatives><graphic"
29,PMC4999195,"rom a phase 1 clinical trial [<xref rid=""pcbi.1005077.ref043"" ref-type=""bibr"">43</xref>]. Since evofosfamide is very quickly eliminated from the blood stream (half-life of 0.81 hours [<xref rid=""pcbi.100"
30,PMC4999195,"mber of hours between doses and <italic>T</italic><sub>2</sub> &#x2265; 6, the concentration of evofosfamide at the blood vessel at time <italic>t</italic> is given by
<disp-formula id=""pcbi.1005077.e030"
31,PMC4999195,"ws the plasma concentration function corresponding to a dosing schedule of 575 mg/m<sup>2</sup> evofosfamide given every week.</p>
          <p>Next we consider how the birth and death rates of sensitive"
32,PMC4999195,he distribution of apoptotic and proliferative markers within tumor tissue after treatment with evofosfamide and showed relatively uniform expression levels with respect to distance from the nearest bloo
33,PMC4999195,"nd DNA damage levels increase. Therefore, unlike with erlotinib, we assume the concentration of evofosfamide in every compartment of the tumor microenvironment at any given time is equal to the concentra"
34,PMC4999195,"c>v</italic><sub><italic>i</italic></sub> is the function describing cell viability in terms of evofosfamide concentration, as defined in <xref ref-type=""supplementary-material"" rid=""pcbi.1005077.s001"">S"
35,PMC4999195,"to treatment with erlotinib, whereas the last <italic>t</italic><sub>2</sub> hours are used for evofosfamide treatment. For the reasons discussed above, given a sufficient amount of time between the last"
36,PMC4999195,"nt. For the reasons discussed above, given a sufficient amount of time between the last dose of evofosfamide in one cycle and the first dose of erlotinib in the next cycle, we may assume that during the "
37,PMC4999195,"in the next cycle, we may assume that during the erlotinib treatment phase there is no residual evofosfamide. Therefore the birth and death rates during the first <italic>t</italic><sub>1</sub> hours in "
38,PMC4999195,"e are governed by erlotinib response kinetics. Since erlotinib has a much longer half-life than evofosfamide, during the last <italic>t</italic><sub>2</sub> hours of evofosfamide treatment it is possible"
39,PMC4999195,"uch longer half-life than evofosfamide, during the last <italic>t</italic><sub>2</sub> hours of evofosfamide treatment it is possible that some erlotinib will remain in the blood stream by the beginning "
40,PMC4999195,"es must reflect responses to both drugs. However, since erlotinib is primarily cytostatic while evofosfamide is primarily cytotoxic, we assume that during this period of time, cellular birth rates reflec"
41,PMC4999195,"irth rates reflect the response to erlotinib while cellular death rates reflect the response to evofosfamide.</p>
          <p>Since cycles are identical, functions describing birth and death rates over "
42,PMC4999195,"                    <td align=""center"" rowspan=""1"" colspan=""1"">sensitive cell birth rate due to evofosfamide</td>
                    <td align=""center"" rowspan=""1"" colspan=""1"">hours<sup>-1</sup> (see <x"
43,PMC4999195,"                    <td align=""center"" rowspan=""1"" colspan=""1"">sensitive cell death rate due to evofosfamide</td>
                    <td align=""center"" rowspan=""1"" colspan=""1"">hours<sup>-1</sup> (see <x"
44,PMC4999195,"                    <td align=""center"" rowspan=""1"" colspan=""1"">resistant cell birth rate due to evofosfamide</td>
                    <td align=""center"" rowspan=""1"" colspan=""1"">hours<sup>-1</sup> (see <x"
45,PMC4999195,"                    <td align=""center"" rowspan=""1"" colspan=""1"">resistant cell death rate due to evofosfamide</td>
                    <td align=""center"" rowspan=""1"" colspan=""1"">hours<sup>-1</sup> (see <x"
46,PMC4999195,"                   </td>
                    <td align=""center"" rowspan=""1"" colspan=""1"">dose of evofosfamide</td>
                    <td align=""center"" rowspan=""1"" colspan=""1"">mg/m<sup>2</sup></td>
    "
47,PMC4999195,"              </td>
                    <td align=""center"" rowspan=""1"" colspan=""1"">time between evofosfamide doses</td>
                    <td align=""center"" rowspan=""1"" colspan=""1"">hours</td>
         "
48,PMC4999195,"                 <td align=""center"" rowspan=""1"" colspan=""1"">plasma concentration after one dose evofosfamide</td>
                    <td align=""center"" rowspan=""1"" colspan=""1""><italic>&#x3BC;</italic>g/"
49,PMC4999195,"2</sub>(<italic>t</italic>)</td>
                    <td align=""center"" rowspan=""1"" colspan=""1"">evofosfamide plasma concentration</td>
                    <td align=""center"" rowspan=""1"" colspan=""1""><ital"
50,PMC4999195,"sub>)</td>
                    <td align=""center"" rowspan=""1"" colspan=""1"">cell viability due to evofosfamide</td>
                    <td align=""center"" rowspan=""1"" colspan=""1"">(see SI section 3)</td>
  "
51,PMC4999195,"               </td>
                    <td align=""center"" rowspan=""1"" colspan=""1"">duration of evofosfamide treatment</td>
                    <td align=""center"" rowspan=""1"" colspan=""1"">hours</td>
     "
52,PMC4999195,"namics of a tumor undergoing therapy with a wide variety of dosing regimens using erlotinib and evofosfamide, both separately and in combination. We first developed a model for the toxicity constraints g"
53,PMC4999195,"olerability data from clinical trials.</title>
              <p>Details regarding erlotinib and evofosfamide dosing schedules tested in clinical trials and how this data informs the construction of the t"
54,PMC4999195,"tr>
                    <td align=""center"" colspan=""5"" rowspan=""1"">
                      <bold>Evofosfamide</bold>
                    </td>
                  </tr>
                  <tr>
              "
55,PMC4999195,"d=""pcbi.1005077.t002"">Table 2</xref>, we construct toxicity constraint curves for erlotinib and evofosfamide. For each drug, we define a function to describe the relationship between maximum tolerated do"
56,PMC4999195,"mml:mrow></mml:mrow></mml:math></alternatives></disp-formula>
The toxicity constraint curve for evofosfamide is given by the following function, where <italic>n</italic> represents the number of times ev"
57,PMC4999195,"ide is given by the following function, where <italic>n</italic> represents the number of times evofosfamide is administered in a 3-week period and <italic>D</italic><sub>2</sub> is the maximum tolerated"
58,PMC4999195,nistered in a 3-week period and <italic>D</italic><sub>2</sub> is the maximum tolerated dose of evofosfamide (in mg/m<sup>2</sup>) associated to the dosing schedule defined by the value of <italic>n</ita
59,PMC4999195,"/label>
            <caption>
              <title>Toxicity constraint curves for erlotinib and evofosfamide.</title>
              <p>These curves depict the maximum tolerated doses of erlotinib (A) and"
60,PMC4999195,".</title>
              <p>These curves depict the maximum tolerated doses of erlotinib (A) and evofosfamide (B) as functions of frequency of dose administration. The black points are the coordinates fro"
61,PMC4999195," that should pass between the last dose of one drug and the first dose of the other drug. Since evofosfamide is eliminated from the blood stream in a matter of a few hours, we assume that as long as six "
62,PMC4999195,"of a few hours, we assume that as long as six or more hours have elapsed since the last dose of evofosfamide, a patient can safely take a dose of erlotinib without the worry of compounding side effects f"
63,PMC4999195,"im to determine the necessary waiting time between a last dose of erlotinib and a first dose of evofosfamide. Since the half-life of erlotinib is much longer than that of evofosfamide, it may not be reas"
64,PMC4999195," and a first dose of evofosfamide. Since the half-life of erlotinib is much longer than that of evofosfamide, it may not be reasonable to wait until erlotinib has been completely eliminated from the bloo"
65,PMC4999195," wait until erlotinib has been completely eliminated from the blood stream before administering evofosfamide, as waiting this long with so little drug in the blood stream could allow the cancer cells to "
66,PMC4999195,"rapidly proliferate. Analysis of clinical trial data for both drugs indicates that erotinib and evofosfamide can both cause skin and mucosal toxicities, but there are no other overlapping toxicities repo"
67,PMC4999195," concentration has fallen to 2.357 <italic>&#x3BC;</italic>M or lower, it is safe to administer evofosfamide since this concentration of erlotinib will not cause any side effects overlapping with those c"
68,PMC4999195,"his concentration of erlotinib will not cause any side effects overlapping with those caused by evofosfamide. Although this is most likely a simplification of the true combination toxicity constraints, w"
69,PMC4999195,edules currently in clinical use. The standard dosing schedule for erlotinib is 150 mg/day. Two evofosfamide dosing schedules have been tested in a clinical trial and designated as maximum tolerated dosi
70,PMC4999195,"edules. Schedule A is the standard erlotinib dosing schedule, and schedules B and C are the two evofosfamide dosing schedules. The remaining schedules (D through J) represent all combination therapies co"
71,PMC4999195,"ination therapies considered in this analysis. Since the toxicity constraints for erlotinib and evofosfamide are formulated in terms of the number of doses administered in a 3-week period, we define thes"
72,PMC4999195,"d=""pcbi.1005077.t003"">Table 3</xref> represent doses of either erlotinib in mg (subscript 1) or evofosfamide in mg/m<sup>2</sup> (subscript 2). For a fixed schedule (column) and day (row), a single entry"
73,PMC4999195," subscripts of 1 are doses of erlotinib in mg and the entries with subscripts of 2 are doses of evofosfamide in mg/m<sup>2</sup>. For a fixed schedule (column) and day (row), a single entry represents th"
74,PMC4999195," schedule (column) and day (row), a single entry represents the one dose of either erlotinib or evofosfamide scheduled for that day. A missing entry for a fixed schedule and day corresponds to a day with"
75,PMC4999195,"y. A missing entry for a fixed schedule and day corresponds to a day with neither erlotinib nor evofosfamide. Two entries for a given schedule on a single day represent the scheduling of two doses, eithe"
76,PMC4999195,"uring treatment with erlotinib alone, the blue curves show the dynamics during monotherapy with evofosfamide, and the green curves show the evolutionary dynamics of the cancer cell population during comb"
77,PMC4999195,"rid=""pcbi.1005077.g004"">Fig 4C</xref> for one of each type of dosing schedule: erlotinib alone, evofosfamide alone, and combination therapy. <xref ref-type=""fig"" rid=""pcbi.1005077.g004"">Fig 4D</xref> sho"
78,PMC4999195," dosing schedules using erlotinib alone are shown in red, results due to dosing schedules using evofosfamide alone are shown in blue, and results due to combination therapies are shown in green. Mean tum"
79,PMC4999195,"regions and erlotinib does not penetrate well to these areas. On the other hand, treatment with evofosfamide alone targets hypoxic regions which comprise the majority of the cell population, leading to a"
80,PMC4999195,"ation therapy, however, the cancer cell population demonstrates an initial steep decline due to evofosfamide, followed by a long-term controlled phase due to the combination of evofosfamide and erlotinib"
81,PMC4999195,"decline due to evofosfamide, followed by a long-term controlled phase due to the combination of evofosfamide and erlotinib. This tight control over the sensitive cell population during combination therap"
82,PMC4999195,"eiving lethal concentrations of erlotinib while cancer cells in hypoxic regions are targeted by evofosfamide. <xref ref-type=""fig"" rid=""pcbi.1005077.g004"">Fig 4D</xref> demonstrates that for the patients"
83,PMC4999195," schedules created by systematically combining standard erlotinib monotherapy with a variety of evofosfamide dosing schedules. However, the amount of time between administration of different drugs can pl"
84,PMC4999195,"o classes are to investigate schedules decreasing the amount of time after erlotinib but before evofosfamide dosing (Class 2), and after evofosfamide but before erlotinib dosing (Class 3).</p>
        <p"
85,PMC4999195,"creasing the amount of time after erlotinib but before evofosfamide dosing (Class 2), and after evofosfamide but before erlotinib dosing (Class 3).</p>
        <p>For each class, we start with a base erl"
86,PMC4999195,"/xref>. Modifications to this schedule are then made to incorporate <italic>n</italic> doses of evofosfamide, where <italic>n</italic> varies from 0 (corresponding to erlotinib monotherapy) to a maximal "
87,PMC4999195,"corresponding to erlotinib monotherapy) to a maximal value <italic>N</italic> (corresponding to evofosfamide monotherapy), in a three-week period. The dose of evofosfamide is determined by the toxicity c"
88,PMC4999195,"lic>N</italic> (corresponding to evofosfamide monotherapy), in a three-week period. The dose of evofosfamide is determined by the toxicity constraint curve in <xref ref-type=""fig"" rid=""pcbi.1005077.g003"""
89,PMC4999195,"<italic>n</italic> hours, consisting of the base erlotinib dosing schedule and a single dose of evofosfamide. This is done using a 4-step process: (i) calculate the evofosfamide dose, (ii) place the evof"
90,PMC4999195,"edule and a single dose of evofosfamide. This is done using a 4-step process: (i) calculate the evofosfamide dose, (ii) place the evofosfamide dose at either <italic>t</italic> = <italic>L</italic> &#x22"
91,PMC4999195,"amide. This is done using a 4-step process: (i) calculate the evofosfamide dose, (ii) place the evofosfamide dose at either <italic>t</italic> = <italic>L</italic> &#x2212; 24 or <italic>t</italic> = <it"
92,PMC4999195,"chedules. In Class 1, we use the standard erlotinib monotherapy schedule of 150 mg/day, and the evofosfamide dose in each cycle is given 24 hours before the start of the next cycle. In Class 2, we use a "
93,PMC4999195,"of 7 mg twice daily, which allows for a shorter waiting period after erlotinib doses and before evofosfamide doses. Class 3 uses the same standard erlotinib monotherapy as in Class 1; however, the evofos"
94,PMC4999195,"sfamide doses. Class 3 uses the same standard erlotinib monotherapy as in Class 1; however, the evofosfamide dose in each cycle is given 6 hours before the start of the next cycle instead of 24, which de"
95,PMC4999195,"ours before the start of the next cycle instead of 24, which decreases the amount of time after evofosfamide doses and before erlotinib doses.</p>
        <p>
<xref ref-type=""fig"" rid=""pcbi.1005077.g005"""
96,PMC4999195,"inib schedule. When <italic>n</italic> = 3, each cycle is one week. So for Classes 1 and 2, the evofosfamide dose in each cycle is given 24 hours before the end of the week, and for Class 3 the evofosfam"
97,PMC4999195,"ofosfamide dose in each cycle is given 24 hours before the end of the week, and for Class 3 the evofosfamide dose in each cycle is given 6 hours before the end of the week. This information is all depict"
98,PMC4999195,"5</xref>. In step 2 (the bottom row), the necessary number of erlotinib doses leading up to the evofosfamide infusion is removed in order to satisfy the combination toxicity constraint. In Classes 1 and "
99,PMC4999195,1 is removed in step 2 to allow the erlotinib concentration to fall sufficiently low before the evofosfamide infusion. Note that in Class 2 the removal of erlotinib is not necessary due to the already lo
100,PMC4999195,"talic> = 3, each cycle has length <italic>L</italic> = 168 (one week). For Classes 1 and 2, the evofosfamide dose in each cycle is given 24 hours before the end of the week, and for Class 3 the evofosfam"
101,PMC4999195,"ofosfamide dose in each cycle is given 24 hours before the end of the week, and for Class 3 the evofosfamide dose in each cycle is given 6 hours before the end of the week. This is all depicted in step 1"
102,PMC4999195,"to the large disparity in the sizes of these results. Furthermore, at the end of treatment with evofosfamide, the tumor primarily consists of sensitive cells, which agrees with our previous observation t"
103,PMC4999195,"he tumor primarily consists of sensitive cells, which agrees with our previous observation that evofosfamide is unable to control the sensitive cell population without erlotinib. Note that some of the me"
104,PMC4999195,"nt. The dosing schedules depicted here include both types of monotherapies (erlotinib alone and evofosfamide alone) from all three optimization classes.</p>
          </caption>
          <alternatives>
"
105,PMC4999195,"        </tr>
                <tr>
                  <td align=""center"" rowspan=""1"" colspan=""1"">Evofosfamide</td>
                  <td align=""center"" rowspan=""1"" colspan=""1"">9 &#x22C5; 10<sup>15</sup></"
106,PMC4999195,"        </tr>
                <tr>
                  <td align=""center"" rowspan=""1"" colspan=""1"">Evofosfamide</td>
                  <td align=""center"" rowspan=""1"" colspan=""1"">3 &#x22C5; 10<sup>17</sup></"
107,PMC4999195,"        </tr>
                <tr>
                  <td align=""center"" rowspan=""1"" colspan=""1"">Evofosfamide</td>
                  <td align=""center"" rowspan=""1"" colspan=""1"">6 &#x22C5; 10<sup>18</sup></"
108,PMC4999195,"ass 1 (blue), Class 2 (red), and Class 3 (yellow) which use a combination of both erlotinib and evofosfamide. Every integer on the <italic>x</italic>-axis represents a combination dosing schedule defined"
109,PMC4999195,"n the <italic>x</italic>-axis represents a combination dosing schedule defined by the number of evofosfamide doses administered in three weeks.</p>
          </caption>
          <graphic xlink:href=""pcb"
110,PMC4999195,"the <italic>x</italic>-axis corresponds to a combination dosing schedule given by the number of evofosfamide doses in a 3-week period, as defined previously.</p>
        <p><italic>Minimize treatment bre"
111,PMC4999195,"n a 3-week period, as defined previously.</p>
        <p><italic>Minimize treatment break after evofosfamide dosing.</italic> Next consider the results due to combination therapy shown in <xref ref-type="
112,PMC4999195,lass 1. This suggests that designing schedules that minimize the amount of time after a dose of evofosfamide and before a dose of erlotinib may lead to better control of the tumor population. This findin
113,PMC4999195,is finding is in agreement with our previous observations that the tumor population response to evofosfamide is strong but short-lived; hence quickly intervening in the subsequent population growth phase
114,PMC4999195," of combination densities (horizontal axis) from monotherapy with erlotinib to monotherapy with evofosfamide, there is a clear region in the interior (approximately <italic>n</italic> = 9&#x2013;17 evofo"
115,PMC4999195,"famide, there is a clear region in the interior (approximately <italic>n</italic> = 9&#x2013;17 evofosfamide doses) where the tumor size and sensitive and resistant population size are minimized. This re"
116,PMC4999195,"2 and 17. This implies that combination therapies incorporating more frequent, smaller doses of evofosfamide result in better treatment outcomes. Even more interestingly, all values of <italic>n</italic>"
117,PMC4999195,s to a dosing schedule which alternates between a single dose of erlotinib and a single dose of evofosfamide. We call these alternating dosing schedules. The dosing schedule corresponding to <italic>n</i
118,PMC4999195," to <italic>n</italic> = 12 in Class 2 consists of two low doses of erlotinib for every dose of evofosfamide, which is still quite similar to the alternating dosing schedules. Thus, even though the optim"
119,PMC4999195," each drug, the optimal therapies were those that utilized close to an equal number of doses of evofosfamide and erlotinib in a sequential alternating fashion.</p>
      </sec>
    </sec>
    <sec sec-ty"
120,PMC4999195,experimental and clinical pharmacokinetic data to investigate potential combinations of the HAP evofosfamide with the targeted tyrosine kinase inhibitor erlotinib against EGFR-activated non small cell lu
121,PMC4999195,n simultaneously (to avoid toxicities) and our model predicted that the complementary action of evofosfamide and erlotinib results in a combined ability to control the tumor&#x2019;s evolution and growth
122,PMC4999195,uction in probability of developing resistance. Deviating significantly from an equal number of evofosfamide and erlotinib doses leads to an increase in both average tumor burden and the probability of d
123,PMC4999195,"</list-item>
        <list-item>
          <p>Strategies minimizing the length of time after an evofosfamide dose and before erlotinib confer further benefits in reduction of tumor burden. The tumor popu"
124,PMC4999195,rlotinib confer further benefits in reduction of tumor burden. The tumor population response to evofosfamide is strong but short-lived; hence quickly intervening in the subsequent population growth phase
125,PMC4999195,g schedules) are likely the most effective because the constant switching between erlotinib and evofosfamide allows the strengths of these drugs to complement one another. Too much time spent taking erlo
126,PMC4999195,trengths of these drugs to complement one another. Too much time spent taking erlotinib without evofosfamide allows the sensitive cell population to remain quite substantial for a long period of time (du
127,PMC4999195," a high probability of a resistance mutation arising. On the other hand, too much time spent on evofosfamide without erlotinib allows the sensitive cell population to expand drastically since evofosfamid"
128,PMC4999195,evofosfamide without erlotinib allows the sensitive cell population to expand drastically since evofosfamide is unable to control its long-term growth. Alternating between these two drugs allows each one
129,PMC4999195,"otinib acts primarily on portions of the tumor microenvironment close to blood vessels, whereas evofosfamide acts primarily on hypoxic regions that are further from the blood stream. Because of this, alt"
130,PMC4999195," This same phenomenon has recently been observed with a different combination therapy utilizing evofosfamide in neuroblastoma and rhabdomyosarcoma preclinical models [<xref rid=""pcbi.1005077.ref048"" ref-"
131,PMC4999195,r evolutionary dynamics during single-agent and combination therapy suggests that erlotinib and evofosfamide may be effective together because they target separate subpopulations within the tumor microen
132,PMC4999195,"pre-existing resistance as well as modeling the bystander effect, which refers to the idea that evofosfamide, once activated in a hypoxic region of the tumor, diffuses outward and affects cancer cells in"
133,PMC4999195,"ype=""bibr"">19</xref>]. In addition, it would be useful to explore the effect of HAPs other than evofosfamide on the probability of developing resistance in order to determine whether the results presente"
134,PMC4999195, developing resistance in order to determine whether the results presented here are specific to evofosfamide or rather are a general phenomenon of HAPs used in combination with tyrosine kinase inhibitors
135,PMC4999195,her are a general phenomenon of HAPs used in combination with tyrosine kinase inhibitors. Since evofosfamide is hypoxia-activated and birth and death rates due to erlotinib are microenvironment-dependent
136,PMC4999195," and results in the manuscript. Specifically, this includes details regarding the erlotinib and evofosfamide plasma concentration function fits. Also included is the derivation of birth and death rates i"
137,PMC4999195,ntration function fits. Also included is the derivation of birth and death rates in response to evofosfamide. The definition of a treatment cycle for the combination dosing strategies is given in full de
138,PMC4999195,"article-title>Combined antitumor therapy with metronic topotecan and hypoxia-activated prodrug, evofosfamide, in neuroblastoma and rhabdomyosarcoma preclinical models</article-title>. <source>Clin Cancer"
0,PMC5033383,"ta-value>All prevalence data used in this study are available from the Open Science Framework. URL: osf.io/h8vsy/</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <n"
1,PMC5033383,"      <p>All prevalence data used in this study are available from the Open Science Framework. URL: osf.io/h8vsy/</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" id=""sec001"">
      <title>"
0,PMC5105998,"-name>
          <meta-value>Data can be found at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/ayw2p/"">https://osf.io/ayw2p/</ext-link>.</meta-value>
        </custom-meta>
      </custom-met"
1,PMC5105998,"value>Data can be found at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/ayw2p/"">https://osf.io/ayw2p/</ext-link>.</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-"
2,PMC5105998,"vailability</title>
      <p>Data can be found at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/ayw2p/"">https://osf.io/ayw2p/</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type"
3,PMC5105998,"   <p>Data can be found at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/ayw2p/"">https://osf.io/ayw2p/</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" id=""sec001"">
 "
0,PMC5242548,"the following identifiers: DOI <ext-link ext-link-type=""uri"" xlink:href=""http://dx.doi.org/10.17605/OSF.IO/FH5U5"">10.17605/OSF.IO/FH5U5</ext-link> and ARK c7605/osf.io/fh5u5.</meta-value>
        </custo"
1,PMC5242548,"rs: DOI <ext-link ext-link-type=""uri"" xlink:href=""http://dx.doi.org/10.17605/OSF.IO/FH5U5"">10.17605/OSF.IO/FH5U5</ext-link> and ARK c7605/osf.io/fh5u5.</meta-value>
        </custom-meta>
      </custom-"
2,PMC5242548,"xlink:href=""http://dx.doi.org/10.17605/OSF.IO/FH5U5"">10.17605/OSF.IO/FH5U5</ext-link> and ARK c7605/osf.io/fh5u5.</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <n"
3,PMC5242548,"the following identifiers: DOI <ext-link ext-link-type=""uri"" xlink:href=""http://dx.doi.org/10.17605/OSF.IO/FH5U5"">10.17605/OSF.IO/FH5U5</ext-link> and ARK c7605/osf.io/fh5u5.</p>
    </notes>
  </front>
"
4,PMC5242548,"rs: DOI <ext-link ext-link-type=""uri"" xlink:href=""http://dx.doi.org/10.17605/OSF.IO/FH5U5"">10.17605/OSF.IO/FH5U5</ext-link> and ARK c7605/osf.io/fh5u5.</p>
    </notes>
  </front>
  <body>
    <sec sec-t"
5,PMC5242548,"xlink:href=""http://dx.doi.org/10.17605/OSF.IO/FH5U5"">10.17605/OSF.IO/FH5U5</ext-link> and ARK c7605/osf.io/fh5u5.</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" id=""sec001"">
      <title>"
0,PMC5322885,"om the Mindboggle Open Science Framework website (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/ydyxu/"">https://osf.io/ydyxu/</ext-link>). The Mindboggle-101 manually edited label data are ava"
1,PMC5322885,"Science Framework website (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/ydyxu/"">https://osf.io/ydyxu/</ext-link>). The Mindboggle-101 manually edited label data are available on the Mindboggl"
2,PMC5322885,"the Mindboggle101 Open Science Framework website (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/nhtur/"">https://osf.io/nhtur/</ext-link>), the Mindboggle-101 Harvard Dataverse website (<ext-li"
3,PMC5322885,"Science Framework website (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/nhtur/"">https://osf.io/nhtur/</ext-link>), the Mindboggle-101 Harvard Dataverse website (<ext-link ext-link-type=""uri"" "
4,PMC5322885,"om the Mindboggle Open Science Framework website (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/ydyxu/"">https://osf.io/ydyxu/</ext-link>). The Mindboggle-101 manually edited label data are ava"
5,PMC5322885,"Science Framework website (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/ydyxu/"">https://osf.io/ydyxu/</ext-link>). The Mindboggle-101 manually edited label data are available on the Mindboggl"
6,PMC5322885,"the Mindboggle101 Open Science Framework website (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/nhtur/"">https://osf.io/nhtur/</ext-link>), the Mindboggle-101 Harvard Dataverse website (<ext-li"
7,PMC5322885,"Science Framework website (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/nhtur/"">https://osf.io/nhtur/</ext-link>), the Mindboggle-101 Harvard Dataverse website (<ext-link ext-link-type=""uri"" "
8,PMC5322885,"> The initial version of the Mindboggle software (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/gfwcn/"">https://osf.io/gfwcn/</ext-link>) was written in Matlab (Mathworks, Inc., Natick, MA) as"
9,PMC5322885,"f the Mindboggle software (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/gfwcn/"">https://osf.io/gfwcn/</ext-link>) was written in Matlab (Mathworks, Inc., Natick, MA) as part of a doctoral dis"
10,PMC5322885,"tml"">http://mindboggle.info/data.html</ext-link>, <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/nhtur/"">https://osf.io/nhtur/</ext-link>) is still the largest publicly available set of manuall"
11,PMC5322885,"info/data.html</ext-link>, <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/nhtur/"">https://osf.io/nhtur/</ext-link>) is still the largest publicly available set of manually edited human brain la"
12,PMC5322885,"nues to be subjected to a variety of evaluations (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/x3up7/"">https://osf.io/x3up7/</ext-link>) and applied in a variety of contexts. In this section,"
13,PMC5322885," a variety of evaluations (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/x3up7/"">https://osf.io/x3up7/</ext-link>) and applied in a variety of contexts. In this section, we compare related sha"
14,PMC5322885,"e=""table"" rid=""pcbi.1005350.t001"">Table 1</xref>; <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/9cn7s/"">https://osf.io/9cn7s/</ext-link>). To compare related (travel and geodesic depth, mean a"
15,PMC5322885,"5350.t001"">Table 1</xref>; <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/9cn7s/"">https://osf.io/9cn7s/</ext-link>). To compare related (travel and geodesic depth, mean and FreeSurfer curvature"
16,PMC5322885,"13</xref>) and in the 40 EMBARC control subjects (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/jwhea/"">https://osf.io/jwhea/</ext-link>). For 16 cortical regions in the 40 subjects, we measur"
17,PMC5322885,"0 EMBARC control subjects (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/jwhea/"">https://osf.io/jwhea/</ext-link>). For 16 cortical regions in the 40 subjects, we measured scan-rescan reliabil"
18,PMC5322885,"ary statistics, and results are available online (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/r95wb/"">https://osf.io/r95wb/</ext-link>). While there was no clear winner, we can summarize our"
19,PMC5322885,"ults are available online (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/r95wb/"">https://osf.io/r95wb/</ext-link>). While there was no clear winner, we can summarize our comparison by computin"
20,PMC5322885,"les, and accompanying plots are available online (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/mhc37/"">https://osf.io/mhc37/</ext-link>).</p>
        <p><bold>Table A</bold> in the <xref ref-"
21,PMC5322885,"lots are available online (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/mhc37/"">https://osf.io/mhc37/</ext-link>).</p>
        <p><bold>Table A</bold> in the <xref ref-type=""supplementary-mat"
22,PMC5322885,"22</xref>] (after transverse temporal cortex; see <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/st7nk/"">https://osf.io/st7nk/</ext-link>), and low scan/rescan consistency for small brain struc"
23,PMC5322885,"verse temporal cortex; see <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/st7nk/"">https://osf.io/st7nk/</ext-link>), and low scan/rescan consistency for small brain structures corroborates Jovi"
24,PMC5322885,"an differences with interhemispheric differences (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/dp4zy/"">https://osf.io/dp4zy/</ext-link>), and using all 101 Mindboggle-101 brains. <bold>Table "
25,PMC5322885,"erhemispheric differences (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/dp4zy/"">https://osf.io/dp4zy/</ext-link>), and using all 101 Mindboggle-101 brains. <bold>Table B</bold> of the <xref r"
26,PMC5322885," rid=""pcbi.1005350.s005"">S5 Supplement</xref> and <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/gzshf/"">https://osf.io/gzshf/</ext-link> for detailed results) [<xref rid=""pcbi.1005350.ref118"" "
27,PMC5322885,""">S5 Supplement</xref> and <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/gzshf/"">https://osf.io/gzshf/</ext-link> for detailed results) [<xref rid=""pcbi.1005350.ref118"" ref-type=""bibr"">118</xr"
28,PMC5322885,"ed from these data (all results are accessible at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/d7hx8/"">https://osf.io/d7hx8/</ext-link>). Each table presents one value for each labeled region"
29,PMC5322885," results are accessible at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/d7hx8/"">https://osf.io/d7hx8/</ext-link>). Each table presents one value for each labeled region or sulcus for each of "
30,PMC5322885,"pcbi.1005350.ref119"" ref-type=""bibr"">119</xref>] (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/d7hx8/"">https://osf.io/d7hx8/</ext-link>). To identify shape measures associated with Alzheimer&"
31,PMC5322885,"f-type=""bibr"">119</xref>] (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/d7hx8/"">https://osf.io/d7hx8/</ext-link>). To identify shape measures associated with Alzheimer&#x2019;s disease, we us"
32,PMC5322885,"    </list-item>
        </list>
        <p>Data: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/ydyxu/"">https://osf.io/ydyxu/</ext-link></p>
        <list list-type=""bullet"">
          <list-i"
33,PMC5322885,"  </list>
        <p>Data: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/ydyxu/"">https://osf.io/ydyxu/</ext-link></p>
        <list list-type=""bullet"">
          <list-item>
            <p>Exa"
34,PMC5322885,"t-item>
            <p>Example preprocessed data: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/8cf5z/"">https://osf.io/8cf5z/</ext-link></p>
          </list-item>
          <list-item>
      "
35,PMC5322885,"Example preprocessed data: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/8cf5z/"">https://osf.io/8cf5z/</ext-link></p>
          </list-item>
          <list-item>
            <p>Anatomical lab"
36,PMC5322885,"tml"">http://mindboggle.info/data.html</ext-link>, <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/nhtur/"">https://osf.io/nhtur/</ext-link></p>
          </list-item>
        </list>
      </sec>"
37,PMC5322885,"info/data.html</ext-link>, <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/nhtur/"">https://osf.io/nhtur/</ext-link></p>
          </list-item>
        </list>
      </sec>
      <sec id=""sec037"""
38,PMC5322885,"tion of Human Brain Mapping [Internet]. 2010. <ext-link ext-link-type=""uri"" xlink:href=""https://mfr.osf.io/render?url=https://osf.io/tmjbn/?action=download%26mode=render"">https://mfr.osf.io/render?url=ht"
39,PMC5322885,"g [Internet]. 2010. <ext-link ext-link-type=""uri"" xlink:href=""https://mfr.osf.io/render?url=https://osf.io/tmjbn/?action=download%26mode=render"">https://mfr.osf.io/render?url=https://osf.io/tmjbn/?action"
40,PMC5322885,"ref=""https://mfr.osf.io/render?url=https://osf.io/tmjbn/?action=download%26mode=render"">https://mfr.osf.io/render?url=https://osf.io/tmjbn/?action=download%26mode=render</ext-link></mixed-citation>
     "
41,PMC5322885,"nder?url=https://osf.io/tmjbn/?action=download%26mode=render"">https://mfr.osf.io/render?url=https://osf.io/tmjbn/?action=download%26mode=render</ext-link></mixed-citation>
      </ref>
      <ref id=""pcb"
42,PMC5322885,"tion of Human Brain Mapping [Internet]. 2014. <ext-link ext-link-type=""uri"" xlink:href=""https://mfr.osf.io/render?url=https://osf.io/w2vda/?action=download%26mode=render"">https://mfr.osf.io/render?url=ht"
43,PMC5322885,"g [Internet]. 2014. <ext-link ext-link-type=""uri"" xlink:href=""https://mfr.osf.io/render?url=https://osf.io/w2vda/?action=download%26mode=render"">https://mfr.osf.io/render?url=https://osf.io/w2vda/?action"
44,PMC5322885,"ref=""https://mfr.osf.io/render?url=https://osf.io/w2vda/?action=download%26mode=render"">https://mfr.osf.io/render?url=https://osf.io/w2vda/?action=download%26mode=render</ext-link></mixed-citation>
     "
45,PMC5322885,"nder?url=https://osf.io/w2vda/?action=download%26mode=render"">https://mfr.osf.io/render?url=https://osf.io/w2vda/?action=download%26mode=render</ext-link></mixed-citation>
      </ref>
      <ref id=""pcb"
46,PMC5322885,"tion of Human Brain Mapping [Internet]. 2015. <ext-link ext-link-type=""uri"" xlink:href=""https://mfr.osf.io/render?url=https://osf.io/xfts3/?action=download%26mode=render"">https://mfr.osf.io/render?url=ht"
47,PMC5322885,"g [Internet]. 2015. <ext-link ext-link-type=""uri"" xlink:href=""https://mfr.osf.io/render?url=https://osf.io/xfts3/?action=download%26mode=render"">https://mfr.osf.io/render?url=https://osf.io/xfts3/?action"
48,PMC5322885,"ref=""https://mfr.osf.io/render?url=https://osf.io/xfts3/?action=download%26mode=render"">https://mfr.osf.io/render?url=https://osf.io/xfts3/?action=download%26mode=render</ext-link></mixed-citation>
     "
49,PMC5322885,"nder?url=https://osf.io/xfts3/?action=download%26mode=render"">https://mfr.osf.io/render?url=https://osf.io/xfts3/?action=download%26mode=render</ext-link></mixed-citation>
      </ref>
      <ref id=""pcb"
0,PMC5352141,"ta are available on the Open Science Framework at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/gtswq/"">https://osf.io/gtswq/</ext-link>.</meta-value>
        </custom-meta>
      </custom-met"
1,PMC5352141," Open Science Framework at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/gtswq/"">https://osf.io/gtswq/</ext-link>.</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-"
2,PMC5352141,"ta are available on the Open Science Framework at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/gtswq/"">https://osf.io/gtswq/</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type"
3,PMC5352141," Open Science Framework at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/gtswq/"">https://osf.io/gtswq/</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" id=""sec001"">
 "
0,PMC5363996,"ta used for testing the software are available at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/9q7dv/"">https://osf.io/9q7dv/</ext-link></meta-value>
        </custom-meta>
      </custom-meta"
1,PMC5363996," software are available at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/9q7dv/"">https://osf.io/9q7dv/</ext-link></meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-m"
2,PMC5363996,"ta used for testing the software are available at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/9q7dv/"">https://osf.io/9q7dv/</ext-link></p>
    </notes>
  </front>
  <body>
    <sec sec-type="
3,PMC5363996," software are available at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/9q7dv/"">https://osf.io/9q7dv/</ext-link></p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" id=""sec001"">
  "
0,PMC5421818,"el code can be found on Open Science Framework at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/bafms/"">https://osf.io/bafms/</ext-link> (Project title: Predicting Explorative Motor Learning U"
1,PMC5421818," Open Science Framework at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/bafms/"">https://osf.io/bafms/</ext-link> (Project title: Predicting Explorative Motor Learning Using Decision-Making an"
2,PMC5421818,"el code can be found on Open Science Framework at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/bafms/"">https://osf.io/bafms/</ext-link> (Project title: Predicting Explorative Motor Learning U"
3,PMC5421818," Open Science Framework at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/bafms/"">https://osf.io/bafms/</ext-link> (Project title: Predicting Explorative Motor Learning Using Decision-Making an"
0,PMC5440054,"xed and single infections are fully available from <ext-link ext-link-type=""uri"" xlink:href=""http://osf.io/a9gwm"">http://osf.io/a9gwm</ext-link>.</meta-value>
        </custom-meta>
      </custom-meta-g"
1,PMC5440054,"ions are fully available from <ext-link ext-link-type=""uri"" xlink:href=""http://osf.io/a9gwm"">http://osf.io/a9gwm</ext-link>.</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-m"
2,PMC5440054,"xed and single infections are fully available from <ext-link ext-link-type=""uri"" xlink:href=""http://osf.io/a9gwm"">http://osf.io/a9gwm</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""i"
3,PMC5440054,"ions are fully available from <ext-link ext-link-type=""uri"" xlink:href=""http://osf.io/a9gwm"">http://osf.io/a9gwm</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" id=""sec001"">
  "
0,PMC5480810,"-name>; <year>2004</year>
<ext-link ext-link-type=""uri"" xlink:href=""http://www.oreilly.com/openbook/osfreesoft/book/"">http://www.oreilly.com/openbook/osfreesoft/book/</ext-link>.</mixed-citation>
      <"
1,PMC5480810,"""uri"" xlink:href=""http://www.oreilly.com/openbook/osfreesoft/book/"">http://www.oreilly.com/openbook/osfreesoft/book/</ext-link>.</mixed-citation>
      </ref>
      <ref id=""pcbi.1005510.ref018"">
       "
0,PMC5549771,"therm/"">http://www.abren.net/protherm/</ext-link>, and specific data sets are given by Dehouck Y, Grosfils A, Folch B, Gilis D, Bogaerts P, Rooman M. Fast and accurate predictions of protein stability ch"
1,PMC5549771,"therm/"">http://www.abren.net/protherm/</ext-link>, and specific data sets are given by Dehouck Y, Grosfils A, Folch B, Gilis D, Bogaerts P, Rooman M. Fast and accurate predictions of protein stability ch"
2,PMC5549771,"pe=""journal"">
<name><surname>Dehouck</surname><given-names>Y</given-names></name>, <name><surname>Grosfils</surname><given-names>A</given-names></name>, <name><surname>Folch</surname><given-names>B</give"
0,PMC5550004,"tational model fits (separate copies deposited on <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/5g9rv"">https://osf.io/5g9rv</ext-link>; <ext-link ext-link-type=""uri"" xlink:href=""https://doi.or"
1,PMC5550004,"eparate copies deposited on <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/5g9rv"">https://osf.io/5g9rv</ext-link>; <ext-link ext-link-type=""uri"" xlink:href=""https://doi.org/10.5281/zenodo.24266"
2,PMC5550004,"tational model fits (separate copies deposited on <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/5g9rv"">https://osf.io/5g9rv</ext-link>; <ext-link ext-link-type=""uri"" xlink:href=""https://doi.or"
3,PMC5550004,"eparate copies deposited on <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/5g9rv"">https://osf.io/5g9rv</ext-link>; <ext-link ext-link-type=""uri"" xlink:href=""https://doi.org/10.5281/zenodo.24266"
0,PMC5604991,"          <meta-value>The data used for this study are available through Open Science Framework at: osf.io/mhxs5.</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <n"
1,PMC5604991,"lity</title>
      <p>The data used for this study are available through Open Science Framework at: osf.io/mhxs5.</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" id=""sec001"">
      <title>"
0,PMC5627944,"le from the Open Science Framework database at <ext-link ext-link-type=""uri"" xlink:href=""http://www.osf.io/qa5k4"">www.osf.io/qa5k4</ext-link>.</meta-value>
        </custom-meta>
      </custom-meta-grou"
1,PMC5627944,"cience Framework database at <ext-link ext-link-type=""uri"" xlink:href=""http://www.osf.io/qa5k4"">www.osf.io/qa5k4</ext-link>.</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-m"
2,PMC5627944,"le from the Open Science Framework database at <ext-link ext-link-type=""uri"" xlink:href=""http://www.osf.io/qa5k4"">www.osf.io/qa5k4</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intr"
3,PMC5627944,"cience Framework database at <ext-link ext-link-type=""uri"" xlink:href=""http://www.osf.io/qa5k4"">www.osf.io/qa5k4</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" id=""sec001"">
  "
0,PMC5716601,"he Open Science Framework database (accession URL: <ext-link ext-link-type=""uri"" xlink:href=""http://osf.io/2xrga"">osf.io/2xrga</ext-link>).</meta-value>
        </custom-meta>
      </custom-meta-group>
"
1,PMC5716601,"e Framework database (accession URL: <ext-link ext-link-type=""uri"" xlink:href=""http://osf.io/2xrga"">osf.io/2xrga</ext-link>).</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-"
2,PMC5716601,"he Open Science Framework database (accession URL: <ext-link ext-link-type=""uri"" xlink:href=""http://osf.io/2xrga"">osf.io/2xrga</ext-link>).</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" "
3,PMC5716601,"e Framework database (accession URL: <ext-link ext-link-type=""uri"" xlink:href=""http://osf.io/2xrga"">osf.io/2xrga</ext-link>).</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" id=""sec001"">
 "
0,PMC5760072,"xist.</p>
        </fn>
        <corresp id=""cor001"">* E-mail: <email>oraf@ekmd.huji.ac.il</email> (OSF); <email>midas@laufercenter.org</email> (DK)</corresp>
      </author-notes>
      <pub-date pub-ty"
1,PMC5760072,"This work was supported by the European Research Council under the ERC Grant Agreement [310873] (to OSF), the USA-Israel Binational Science Foundation [2009418] (to OSF &amp; DK), and NSF grants DBI 1458"
2,PMC5760072,"e ERC Grant Agreement [310873] (to OSF), the USA-Israel Binational Science Foundation [2009418] (to OSF &amp; DK), and NSF grants DBI 1458509 and AF 1527292 (to DK). The funders had no role in study desi"
0,PMC5780187,"   <meta-value>All relevant data are available at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/semkz/"">https://osf.io/semkz/</ext-link>.</meta-value>
        </custom-meta>
      </custom-met"
1,PMC5780187,"vant data are available at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/semkz/"">https://osf.io/semkz/</ext-link>.</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-"
2,PMC5780187,"itle>
      <p>All relevant data are available at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/semkz/"">https://osf.io/semkz/</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type"
3,PMC5780187,"vant data are available at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/semkz/"">https://osf.io/semkz/</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" id=""sec001"">
 "
0,PMC5825175,"anuscript is available on Open Science framework (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/kbz3j/"">https://osf.io/kbz3j/</ext-link>).</meta-value>
        </custom-meta>
      </custom-me"
1,PMC5825175,"on Open Science framework (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/kbz3j/"">https://osf.io/kbz3j/</ext-link>).</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article"
2,PMC5825175,"anuscript is available on Open Science framework (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/kbz3j/"">https://osf.io/kbz3j/</ext-link>).</p>
    </notes>
  </front>
  <body>
    <sec sec-typ"
3,PMC5825175,"on Open Science framework (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/kbz3j/"">https://osf.io/kbz3j/</ext-link>).</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" id=""sec001"">
"
0,PMC5833290,"names></name>, <name><surname>Ostblom</surname><given-names>J</given-names></name>, <name><surname>Posfai</surname><given-names>E</given-names></name>, <name><surname>Rossant</surname><given-names>J</giv"
0,PMC5864083,"d on Open Science Framework, DOI <ext-link ext-link-type=""uri"" xlink:href=""https://doi.org/10.17605/OSF.IO/M25N4"">10.17605/OSF.IO/M25N4</ext-link>: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.i"
1,PMC5864083,"work, DOI <ext-link ext-link-type=""uri"" xlink:href=""https://doi.org/10.17605/OSF.IO/M25N4"">10.17605/OSF.IO/M25N4</ext-link>: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/M25N4/"">https://osf.i"
2,PMC5864083,"5/OSF.IO/M25N4"">10.17605/OSF.IO/M25N4</ext-link>: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/M25N4/"">https://osf.io/M25N4/</ext-link>.</meta-value>
        </custom-meta>
      </custom-met"
3,PMC5864083,"5/OSF.IO/M25N4</ext-link>: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/M25N4/"">https://osf.io/M25N4/</ext-link>.</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-"
4,PMC5864083,"d on Open Science Framework, DOI <ext-link ext-link-type=""uri"" xlink:href=""https://doi.org/10.17605/OSF.IO/M25N4"">10.17605/OSF.IO/M25N4</ext-link>: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.i"
5,PMC5864083,"work, DOI <ext-link ext-link-type=""uri"" xlink:href=""https://doi.org/10.17605/OSF.IO/M25N4"">10.17605/OSF.IO/M25N4</ext-link>: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/M25N4/"">https://osf.i"
6,PMC5864083,"5/OSF.IO/M25N4"">10.17605/OSF.IO/M25N4</ext-link>: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/M25N4/"">https://osf.io/M25N4/</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type"
7,PMC5864083,"5/OSF.IO/M25N4</ext-link>: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/M25N4/"">https://osf.io/M25N4/</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" id=""sec001"">
 "
0,PMC5877903,"<meta-value>All datasets are freely available at: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/ke9r7/?view_only=ff19ba1bf67f406ab044572328b10b26"">https://osf.io/ke9r7/?view_only=ff19ba1bf67f4"
1,PMC5877903,"nk-type=""uri"" xlink:href=""https://osf.io/ke9r7/?view_only=ff19ba1bf67f406ab044572328b10b26"">https://osf.io/ke9r7/?view_only=ff19ba1bf67f406ab044572328b10b26</ext-link>.</meta-value>
        </custom-meta"
2,PMC5877903,"e>
      <p>All datasets are freely available at: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/ke9r7/?view_only=ff19ba1bf67f406ab044572328b10b26"">https://osf.io/ke9r7/?view_only=ff19ba1bf67f4"
3,PMC5877903,"nk-type=""uri"" xlink:href=""https://osf.io/ke9r7/?view_only=ff19ba1bf67f406ab044572328b10b26"">https://osf.io/ke9r7/?view_only=ff19ba1bf67f406ab044572328b10b26</ext-link>.</p>
    </notes>
  </front>
  <bod"
0,PMC5886625," are available from the Open Science Framework at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/52mf4/"">https://osf.io/52mf4/</ext-link>.</meta-value>
        </custom-meta>
      </custom-met"
1,PMC5886625," Open Science Framework at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/52mf4/"">https://osf.io/52mf4/</ext-link>.</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-"
2,PMC5886625," are available from the Open Science Framework at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/52mf4/"">https://osf.io/52mf4/</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type"
3,PMC5886625," Open Science Framework at <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/52mf4/"">https://osf.io/52mf4/</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" id=""sec001"">
 "
0,PMC5940245,"drion/Files/Drionetal2018-Code.zip</ext-link> and <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/k86en"">https://osf.io/k86en</ext-link>.</meta-value>
        </custom-meta>
      </custom-meta-"
1,PMC5940245,"018-Code.zip</ext-link> and <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/k86en"">https://osf.io/k86en</ext-link>.</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-m"
2,PMC5940245,"drion/Files/Drionetal2018-Code.zip</ext-link> and <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/k86en"">https://osf.io/k86en</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type="""
3,PMC5940245,"018-Code.zip</ext-link> and <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/k86en"">https://osf.io/k86en</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" id=""sec001"">
  "
4,PMC5940245,"les/Drionetal2018-Code.zip</ext-link> and <italic><ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/k86en"">https://osf.io/k86en</ext-link></italic>.</p>
      <p>Single-compartment Hodgkin-Huxley "
5,PMC5940245,".zip</ext-link> and <italic><ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/k86en"">https://osf.io/k86en</ext-link></italic>.</p>
      <p>Single-compartment Hodgkin-Huxley models were used for a"
0,PMC5944912,"anuscript is available on Open Science Framework (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/vy9s7/"">https://osf.io/vy9s7/</ext-link>).</meta-value>
        </custom-meta>
      </custom-me"
1,PMC5944912,"on Open Science Framework (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/vy9s7/"">https://osf.io/vy9s7/</ext-link>).</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article"
2,PMC5944912,"anuscript is available on Open Science Framework (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/vy9s7/"">https://osf.io/vy9s7/</ext-link>).</p>
    </notes>
  </front>
  <body>
    <sec sec-typ"
3,PMC5944912,"on Open Science Framework (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/vy9s7/"">https://osf.io/vy9s7/</ext-link>).</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" id=""sec001"">
"
0,PMC6051643,"ata and code available on Open Science Framework: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/fu9be/"">https://osf.io/fu9be/</ext-link>.</meta-value>
        </custom-meta>
      </custom-met"
1,PMC6051643,"on Open Science Framework: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/fu9be/"">https://osf.io/fu9be/</ext-link>.</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-"
2,PMC6051643,"ata and code available on Open Science Framework: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/fu9be/"">https://osf.io/fu9be/</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type"
3,PMC6051643,"on Open Science Framework: <ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/fu9be/"">https://osf.io/fu9be/</ext-link>.</p>
    </notes>
  </front>
  <body>
    <sec sec-type=""intro"" id=""sec001"">
 "
4,PMC6051643,"are available on our open-access data depository (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/fu9be/"">https://osf.io/fu9be/</ext-link>).</p>
      <p>We found that older adults won fewer tot"
5,PMC6051643,"en-access data depository (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/fu9be/"">https://osf.io/fu9be/</ext-link>).</p>
      <p>We found that older adults won fewer total points than younger "
6,PMC6051643,"are available on our open-access data depository (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/fu9be/"">https://osf.io/fu9be/</ext-link>).</p>
      </sec>
      <sec id=""sec007"">
        <tit"
7,PMC6051643,"en-access data depository (<ext-link ext-link-type=""uri"" xlink:href=""https://osf.io/fu9be/"">https://osf.io/fu9be/</ext-link>).</p>
      </sec>
      <sec id=""sec007"">
        <title>Motor gambling task<"
